CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback